Over 16,000 Olongapo residents now fully jabbed vs COVID-19 | Inquirer News

Over 16,000 Olongapo residents now fully jabbed vs COVID-19

Olongapo City continues to vaccinate eligible residents on the priority list. (Photo courtesy of the Olongapo City Information Center)

OLONGAPO CITY––At least 1,170 residents here got their second dose of the AstraZeneca COVID-19 vaccine on Thursday, the city information center said.

The latest vaccine recipients pushed the number of fully inoculated residents in the city to about 16,000.

ADVERTISEMENT

An interval of one to three months has been recommended for the two doses of the COVID-19 vaccine made by British-Swede pharmaceutical firm AstraZeneca.

FEATURED STORIES

Over 15 million doses of the AstraZeneca are expected to be received by the country until 2022 through the COVAX Facility that aims to ensure equitable access to limited anti-COVID shots.

The city has been administering AstraZeneca, Sinovac, and the single-shot Janssen vaccine of Johnson & Johnson to eligible city residents.

Olongapo aims to vaccinate 70 percent of its 260,000-population to achieve herd immunity against COVID-19. INQ

lzb

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: AstraZeneca, COVID-19, Olongapo City, Regions, vaccine

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.